pifithrin has been researched along with Ischemic Attack, Transient in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Niizuma, K | 1 |
| Endo, H | 1 |
| Nito, C | 1 |
| Myer, DJ | 1 |
| Chan, PH | 1 |
1 other study available for pifithrin and Ischemic Attack, Transient
| Article | Year |
|---|---|
Potential role of PUMA in delayed death of hippocampal CA1 neurons after transient global cerebral ischemia.
Topics: Animals; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; Benzothiazoles; B | 2009 |